England and colleagues developed [89Zr]Zr-DFO-nivolumab that was able to bind PD-1+ T cells in vivo in the tumor and salivary glands of a murine model with a maximum uptake at 168 hours post-injection [145]. This evidence concerns the gene PDCD1 and neoplasm.